Clinical trial · no report yet · Phase 3
NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
- NCT04622319 ↗
- Active not recruiting
- Daiichi Sankyo
- 236 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 90 | |
| X threads | 85 | |
| Podcasts | 55 | |
| X videos | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer
- Interventions
- DS-8201a; T-DM1
- Arms
- Trastuzumab deruxtecan (T-DXd) · Experimental
- Trastuzumab ematansine (T-DM1) · Active comparator
- Enrollment
- 1,600 (estimated)
- Primary outcomes
- Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment
- Sponsor
- Daiichi Sankyo with AstraZeneca, NSABP Foundation Inc, GBG Forschungs GmbH, Spanish Breast Cancer Research Group
- Start
- Dec 4, 2020
- Primary completion
- Jul 2, 2025
- Results posted
- No
- Registry record
- NCT04622319 · updated May 15, 2026
Publications
linked from the registry- Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, Li W, Li H, Wang Y, Yao H, Kim SB, Geng CZ, Rodriguez Pantigoso W, Ramirez Godinez FJ, Song C, Ching Chang Y, Antoniazzi A, Chen SC, Li Z, Nowecki Z, Lim J, Mathias E, Sato Y, Lu W, Abdel-Monem H, Untch M, Geyer CE Jr; DESTINY-Breast05 Trial Investigators. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N Engl J Med. 2026 Feb 26;394(9):845-857. doi: 10.1056/NEJMoa2514661. Epub 2025 Dec 10. PubMed 41370739
- Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli MA, Bergh J, Foukakis T, Matikas A. Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2025 Mar 12;23(4):e247093. doi: 10.6004/jnccn.2024.7093. PubMed 40073831